Association of High Expression of Groβ with Clinical and Pathological Characteristics of Unfavorable Prognosis in Gastrointestinal Stromal Tumors

Table 3

Univariate and multivariable analysis of prognostic factors in GIST for 5-year and 10-year survival.

Variable	Years	Univariate analysis			Multivariate analysis
		HR	value	95% CI	HR	value	95% CI
Cytoplasmic expression of GROβ
High versus low	10	2.521	0.009^*	1.263–5.033	2.479	0.023^*	1.135–5.418
	5	2.290	0.033^*	1.071–4.895	1.927	0.133	0.819–4.537
Nuclear expression of GROβ
High versus low	10	3.280	0.001^*	1.611–6.677	2.082	0.071	0.939–4.619
	5	3.637	0.002^*	1.631–8.110	2.039	0.111	0.849–4.898
Age (years)
60 versus >60	10	1.215	0.583	0.606–2.435
	5	1.080	0.841	0.507–2.300
Tumor size (cm)
	10	2.265	0.002^*	1.360–3.772	3.182	0.076	0.884–11.448
	5	1.992	0.015^*	1.145–3.466	3.559	0.098	0.792-15.982
Mitotic index (per 50 HPFs)
0–5 versus >6	10	3.038	0.001^*	1.869–4.937	2.695	0.095	0.842–8.632
	5	3.737	0.001^*	2.117–6.598	6.086	0.026^*	1.240–29.869
Growth pattern
Single versus multiple	10	1.381	0.475	0.569–3.349
	5	1.472	0.435	0.557–3.888
Tumor location
Stomach versus intestine versus others	10	1.357	0.218	0.835–2.203
	5	1.320	0.306	0.776–2.245
AFIP-Miettinen risk classification
Very low-low risk versus moderate-high risk	10	2.374	0.001^*	1.617–3.484	3.011	0.120	0.751–12.064
	5	2.368	0.001^*	1.159–3.553	2.311	0.315	0.450–11.865

^*; HPF: high-power fields.